Group 1 - The core viewpoint of the article highlights that Hua Yan Biotech-B (02396) has seen a significant decline in its stock price, dropping over 12% to a new low of 18.6 HKD, which is a substantial decrease from its IPO price of 38.2 HKD [1] - As of the latest report, the company's stock is trading at 18.67 HKD with a trading volume of 746.2 million HKD [1] - Hua Yan Biotech is a biopharmaceutical company focused on the discovery, development, and commercialization of wound healing therapies [1] Group 2 - The company has a pipeline of ten candidate products scheduled for development by December 5, 2025, with seven of these being PDGF candidate drugs, including two core products, Pro-101-1 and Pro-101-2 [1] - Financially, the company has not generated any revenue from product sales, reporting net losses of 110 million, 210 million, and 130 million for the years 2023, 2024, and up to September 30, 2025, respectively [1] - The majority of the company's net losses are attributed to research and development expenses as well as administrative costs [1]
港股异动 | 华芢生物-B(02396)早盘跌超12%创新低 较招股价已腰斩